FY2026 Earnings Forecast for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at William Blair issued their FY2026 EPS estimates for Twist Bioscience in a research note issued on Monday, November 18th. William Blair analyst M. Larew forecasts that the company will earn ($1.50) per share for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share.

TWST has been the subject of several other reports. Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.78.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $41.89 on Wednesday. The firm’s 50 day moving average price is $43.93 and its 200-day moving average price is $46.15. The company has a market cap of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78. Twist Bioscience has a 52-week low of $23.07 and a 52-week high of $60.90.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 1,057 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the transaction, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now directly owns 589,552 shares in the company, valued at approximately $26,294,019.20. This represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. increased its stake in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares during the period. Caprock Group LLC increased its position in Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares during the period. Signaturefd LLC increased its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. Arizona State Retirement System increased its position in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after purchasing an additional 312 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.